| アブストラクト | OBJECTIVE: The clinical evidence linking medications to retinal detachment (RD) remains limited. This study utilises real-world data from the U.S. FDA Adverse Event Reporting System (FAERS) to identify drugs associated with RD and characterise their classifications. METHODS: A disproportionality analysis was performed on over 17 million FAERS reports. Drugs with statistically significant disproportionate RD reporting were identified and categorised by therapeutic class, signal strength, latency period, subgroup factors (e.g., off-label use, age, gender, subtypes, regions), and sensitivity analysis. RESULTS: Thirty drugs showed significant associations with RD, including ophthalmic agents, anticancer therapies, corticosteroids, and erectile dysfunction medications. Signal strength varied: pilocarpine, encorafenib, and ocriplasmin exhibited the highest signal strength, while prednisolone and bevacizumab showed lower strength. Latency periods differed significantly: erectile dysfunction drugs had the longest median latency (365 days), whereas anticancer drugs had the shortest (14 days). Subgroup analyses revealed elevated RD signal strength with off-label use and distinct susceptibility patterns: younger adults (<65) and males had higher signal strength for specific drug classes (e.g., ophthalmic agents), while older adults (>65) were more susceptible to RD with corticosteroids. Subtype analysis highlighted drug-specific associations with exudative, tractional, and rhegmatogenous RD. Sensitivity analysis restricted to healthcare professional reports further confirmed the robustness of the findings. CONCLUSIONS: This study provides a stratified list of medications with disproportionate reporting signals for RD. Further high-quality epidemiological and mechanistic studies are warranted to validate the potential causality associations between these medications and RD. Assessment of drug-related retinal detachment using real-world large-scale data. |
|---|
| ジャーナル名 | Eye (London, England) |
|---|
| Pubmed追加日 | 2025/10/11 |
|---|
| 投稿者 | Chen, Xiao-Dong; Xiao, Kun-Hong; Wu, Shi-Nan; Wei, Ming-Yan; Yu, Chao-Feng; Feng, Ke; Cai, Pei-Xin; Wang, Yu-Ru; Miao, Yan-Liang; Li, Li; Wang, Bo-Zhao; Li, Shi-Ying; Chen, Qian |
|---|
| 組織名 | Department of Ophthalmology, The First Affiliated Hospital of Xiamen University,;Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian;Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of;Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.;Department of Ophthalmology and Optometry, Fujian Medical University, Fuzhou,;China.;Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial;Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.;Department of Stomatology, Xiang'an Hospital of Xiamen University, School of;Medicine, Xiamen University, Xiamen, Fujian, China.;shiying_li@126.com.;China. shiying_li@126.com.;qchen2@xmu.edu.cn.;Department of Ophthalmology, Xiang'an Hospital of Xiamen University, Xiamen,;Fujian, China. qchen2@xmu.edu.cn. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41073807/ |
|---|
